Literature DB >> 25721372

Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation.

Stef P Menting1, Paul M Dekker, Jacqueline Limpens, Lotty Hooft, Phyllis I Spuls.   

Abstract

There is a range of methotrexate dosing regimens for psoriasis. This review summarizes the evidence for test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and use of folic acid. A literature search for randomized controlled trials and guidelines was performed. Twenty-three randomized controlled trials (29 treatment groups) and 10 guidelines were included. Two treatment groups used a test-dose, 5 guidelines recommend it. The methotrexate start-dose in randomized controlled trials varied from 5 to 25 mg/week, most commonly being either 7.5 mg or 15 mg. Guidelines vary from 5 to 15 mg/week. Methotrexate was administered as a single dose or in a Weinstein schedule in 15 and 11 treatment-groups, respectively; both recommended equally in guidelines. A fixed dose (n = 18), predefined dose (n = 3), or dose adjusted on clinical improvement (n = 8) was used, the last also being recommended in guidelines. Ten treatment groups used folic acid; in 2 it was allowed, in 14 not mentioned, and in 3 no folic acid was used. Most guidelines recommend the use of folic acid. Authors' suggestions for methotrexate dosing are given.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 25721372     DOI: 10.2340/00015555-2081

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  7 in total

1.  Antipsoriatic Potential of Quebecol and Its Derivatives.

Authors:  Corinne Bouchard; Alexe Grenier; Sébastien Cardinal; Sarah Bélanger; Normand Voyer; Roxane Pouliot
Journal:  Pharmaceutics       Date:  2022-05-26       Impact factor: 6.525

Review 2.  Challenge of Nail Psoriasis: An Update Review.

Authors:  Chao Ji; Haiqing Wang; Chengbei Bao; Liangliang Zhang; Shifan Ruan; Jing Zhang; Ting Gong; Bo Cheng
Journal:  Clin Rev Allergy Immunol       Date:  2021-09-03       Impact factor: 8.667

3.  Optimizing adalimumab treatment in psoriasis with concomitant methotrexate (OPTIMAP): study protocol for a pragmatic, single-blinded, investigator-initiated randomized controlled trial.

Authors:  C I Busard; S P Menting; J S van Bezooijen; J M van den Reek; B A Hutten; E P Prens; E M de Jong; M B van Doorn; P I Spuls
Journal:  Trials       Date:  2017-02-02       Impact factor: 2.279

4.  Dermatological guidelines for monitoring methotrexate treatment reduce drug-survival compared to rheumatological guidelines.

Authors:  Felien T M Busger Op Vollenbroek; Carine J M Doggen; René W A Janssens; Hein J Bernelot Moens
Journal:  PLoS One       Date:  2018-03-23       Impact factor: 3.240

5.  Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.

Authors:  H Dickel; T Bruckner; P Altmeyer
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-05-18       Impact factor: 6.166

6.  Serum Metabolomic Profiling Reveals the Amelioration Effect of Methotrexate on Imiquimod-Induced Psoriasis in Mouse.

Authors:  Jiaxin Zong; Jieyi Cheng; Yuanfeng Fu; Jing Song; Weisong Pan; Li Yang; Ting Zhang; Mingmei Zhou
Journal:  Front Pharmacol       Date:  2020-11-19       Impact factor: 5.810

7.  Use of Methotrexate in the Treatment of Moderate to Severe Plaque Psoriasis in France: A Practice Survey.

Authors:  Anne-Claire Fougerousse; Laure Mery-Bossard; Josiane Parier; Charles Taieb; Antoine Bertolotti; Francois Maccari
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-04-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.